Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog
Bristol-Myers Squibb Company
) received encouraging news when the Japanese Ministry of Health,
Labour and Welfare (MHLW) cleared its combination therapy of
Daklinza (daclatasvir) and Sunvepra (asunaprevir) for treating
patients suffering from the genotype 1 strain of chronic hepatitis
C virus (HCV), including those affected by compensated cirrhosis.
While Daklinza is a NS5A replication complex inhibitor, Sunvepra is
a NS3/4A protease inhibitor.
Approval was gained on the basis of encouraging data from a phase III study which showed that the combination of Daklinza and Sunvepra achieved an overall sustained virologic response of 84.7% after 24 weeks of treatment in Japanese patients suffering from genotype 1b version of HCV. The patients were either ineligible for or intolerant to interferon therapy or non-responders to the same. Bristol-Myers had sought Japanese approval for the dual regimen late last year.
Bristol-Myers stated in its press release that this marked the first interferon-free and ribavirin-free therapy to be approved in Japan for treating HCV. The biopharmaceutical major further noted that interferon-based therapies are the current standard of care for treating HCV patients.
Gilead Sciences ( GILD ) intends to seek Japanese approval of a fixed dose combination of ledipasvir and its highly successful HCV treatment Sovaldi in genotype 1 patients by year end.
The HCV market is highly lucrative worldwide. Japan particularly offers significant commercial potential making us highly bullish on the approval. As per Bristol-Myers, in Japan alone 1.2 million people are estimated to be affected by HCV. The company further stated that approximately 70% of the HCV affected population suffer from genotype 1b of the infection. Moreover, people aged over 65 years form a significant portion of the HCV affected population in Japan. It decreases the probability of elderly patients tolerating interferon-based medications, which are associated with serious side effects.
Bristol-Myers is looking to get Daklinza-based regimens approved in the U.S. (target date: Nov 30, 2014) and EU (under review) for treating HCV. We expect investor focus to remain on updates regarding the development of Bristol-Myers' HCV pipeline.
Bristol-Myers carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Actelion ( ALIOF ) and Biogen Idec ( BIIB ). Both are Zacks Ranked #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research